Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...

Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...

Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...